GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
GlaxoSmithKline Pharmaceuticals announced its Q4 and full-year FY26 financial results, reporting continued profitable growth. The company also declared a final dividend of Rs.57 per equity share, reflecting strong performance and an expanded product portfolio.
May 13 2026 15:05:00
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
GlaxoSmithKline Pharmaceuticals presented its investor meeting materials for FY26, providing a comprehensive overview of financial performance, strategic initiatives, market positioning of key brands, and ongoing clinical development pipeline across various therapeutic areas.
May 13 2026 15:05:00
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Corporate Action-Board approves Dividend
GlaxoSmithKline recommended a final dividend of ₹57 per equity share for FY26. This is higher than the ₹54 total dividend paid in FY25, reflecting improved shareholder returns. The record date is May 29, 2026.
May 13 2026 15:05:00
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Record Date For Final Dividend 29Th May 2026
GSK Pharma set May 29, 2026, as the Record Date for its final dividend of ₹57 per equity share for FY26. Payment to eligible shareholders is scheduled on or after July 1, 2026.
May 13 2026 15:05:00
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Board Meeting Intimation for Audited Financial Results (Standalone & Consolidated) For The Year Ended 31St March 2026 And Dividend If Any
GlaxoSmithKline Pharmaceuticals board will convene on May 13, 2026. The meeting will focus on approving the audited financial results for Q4 FY26 and the full financial year, and considering a dividend recommendation.
Apr 22 2026 12:04:00
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals' Board authorized key personnel to determine the materiality of any event or transaction for stock exchange disclosures. This ensures compliance with SEBI Regulation 30(5). The authorized individuals include the Managing Director, CFO, Company Secretary, and Head of Legal.
Apr 21 2026 11:04:00
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals appointed Vinay Subramanian as Commercial Head - Oncology. He brings over 24 years of experience from various sectors like Pharmaceuticals and Life Science, previously holding leadership roles at Roche and GE Healthcare.
Apr 21 2026 11:04:00
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline's board approved the appointment of Mr. Ronojit Biswas as Executive Director for a 36-month term, effective April 1, 2026. This appointment leverages his 25 years of experience with GSK across various international markets and leadership roles.
Apr 21 2026 10:04:00
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals appointed Mr. Vinay Subramanian, Commercial Head – Oncology, to its leadership team, effective April 20, 2026. He has over 24 years of experience in pharmaceuticals and healthcare.
Apr 21 2026 10:04:00
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Change in Management
GlaxoSmithKline Pharmaceuticals Limited (GSK) appoints Mr. Vinay Subramanian, Commercial Head – Oncology, to its leadership team as Senior Management Personnel, effective April 20, 2026. Subramanian has over 24 years of experience in pharma and healthcare, previously with Roche and GE Healthcare.
Apr 21 2026 10:04:00
Read More